Traws Pharma's Ratutrelvir Shows Favorable Tolerability in COVID-19 Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 Dec 25
Source: Globenewswire
Traws Pharma Inc's stock surged by 17.27% in pre-market trading, crossing above the 5-day SMA, amid positive market conditions with the Nasdaq-100 up 0.41% and the S&P 500 up 0.30%.
The increase is attributed to Traws Pharma's announcement of favorable preliminary results for Ratutrelvir in a COVID-19 treatment trial, demonstrating a better tolerability profile compared to PAXLOVID™, which may enhance its market potential and competitive position.
This positive news regarding Ratutrelvir's efficacy and safety could attract more investors, potentially leading to sustained interest in Traws Pharma's stock as it positions itself in the COVID-19 treatment landscape.
Analyst Views on TRAW
Wall Street analysts forecast TRAW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRAW is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.460
Low
8.00
Averages
8.00
High
8.00
Current: 2.460
Low
8.00
Averages
8.00
High
8.00
About TRAW
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
